Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible
for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have
either exhausted treatment options or are not eligible for, suitable for, or willi...
Age: 18 years - 66+
Gender: All
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to
evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in
anti-PD-1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The
contributions...
Age: 18 years - 66+
Gender: All
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in
combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in
metastatic melanoma. This study will explore the Efficacy and Safety of UV1 administere...
Age: 18 years - 66+
Gender: All
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm
the safety of VV1 in combination with cemiplimab. The study will enroll patients with two
distinct advanced malignancies in separate tumor cohorts. The two cancers types ar...
Age: 18 years - 66+
Gender: All
A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully
human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human
antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for ...
Age: 12 years - 66+
Gender: All
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination
with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the most appropriate dose for the combination of
ibrutinib and pembrolizumab and to see if the combination is active for the disease. The
study will monitor for any side effects and if the combination of ibrutinib and pembro...
Age: 18 - 99 years
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
The purpose of this study is to determine the initial safety profile and initial antitumor
activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab]
with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 ...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human
immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not
respond to treatment (refractory), or have distributed over a large area in the b...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Ge...
Age: 18 years - 66+
Gender: All